TRT for Muscle Loss: Does Testosterone Replacement Therapy Actually Work?

What Causes Muscle Loss in Men With Low Testosterone?

Testosterone drives protein synthesis in skeletal muscle by binding androgen receptors on myocytes and activating mTOR signaling. When serum levels fall below 300 ng/dL, anabolic signaling drops, protein breakdown outpaces synthesis, and men lose both muscle fiber size and satellite cell activity needed for repair. A 2001 dose-response study published in NEJM showed that lean body mass increased linearly from the lowest testosterone dose (25 mg/week) up to 600 mg/week in healthy men, confirming a direct, concentration-dependent relationship between testosterone and muscle [1].

Aging compounds the problem. Testosterone declines roughly 1-2% per year after age 30 [2]. By their mid-50s, approximately 20% of men meet biochemical criteria for hypogonadism, and that figure rises to nearly 30% by age 70 according to CDC-cited population surveillance data [2]. Muscle loss tied to this decline is not simply cosmetic. Lower muscle mass predicts falls, fractures, insulin resistance, and all-cause mortality in men over 50.

The loss is also self-reinforcing. Less muscle means lower resting metabolic rate, which encourages fat gain. Adipose tissue aromatizes testosterone to estradiol, which further suppresses luteinizing hormone (LH) output from the pituitary and deepens the testosterone deficit. Breaking that cycle usually requires addressing the hormonal root cause directly.

Primary vs. Secondary Hypogonadism: Why the Distinction Matters for Treatment

Primary and secondary hypogonadism are not interchangeable diagnoses, and the correct label changes how TRT is prescribed. Primary hypogonadism means the testes themselves fail to produce adequate testosterone despite high LH stimulation. Secondary hypogonadism, also called hypogonadotropic hypogonadism, means the pituitary or hypothalamus fails to send the LH signal, so LH is low or inappropriately normal even when testosterone is deficient [3].

The Endocrine Society's 2018 Clinical Practice Guideline distinguishes the two clearly: "We recommend measurement of morning total testosterone level as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning total testosterone level" [3].

For primary hypogonadism (high LH, low testosterone, causes include Klinefelter syndrome, testicular trauma, or chemotherapy), exogenous testosterone is the standard approach because the testes cannot respond to any stimulation. For secondary hypogonadism (low LH, low testosterone), fertility-preserving alternatives such as clomiphene citrate 25-50 mg daily or human chorionic gonadotropin (hCG) 500-1 to 500 IU three times weekly may restore testosterone while maintaining sperm production [4]. A 2019 systematic review in JCEM found clomiphene produced mean testosterone increases from 232 to 612 ng/dL across pooled data [4]. Men who want biological children should discuss these options before starting exogenous testosterone, which suppresses spermatogenesis.

Late-onset hypogonadism, sometimes called andropause, occupies a specific clinical space. The European Male Ageing Study (EMAS), published in NEJM in 2010 (N=3,369), defined late-onset hypogonadism as a total testosterone below 11 nmol/L (317 ng/dL) combined with at least three sexual symptoms: low libido, poor morning erections, or erectile dysfunction [5]. That study found only 2.1% of community-dwelling men aged 40-79 met the full symptomatic plus biochemical threshold, cautioning against over-diagnosis.

What TRT Actually Does to Lean Mass: The Clinical Evidence

The TTrials are the clearest benchmark. This NIH-sponsored placebo-controlled trial enrolled 790 men aged 65 and older with total testosterone below 275 ng/dL and assigned them to testosterone gel 1% or placebo for 12 months [6]. The Physical Function Trial sub-study showed testosterone-treated men gained 3.4 kg of lean mass versus 0.7 kg in placebo (P<0.001). Leg strength increased by 13.3 Newtons versus 3.1 Newtons in placebo [6].

A 2006 meta-analysis in JCEM pooled 29 randomized controlled trials and found TRT increased lean body mass by a weighted mean of 1.7 kg and reduced fat mass by 1.6 kg [7]. Effects were larger in men with more severely deficient baseline testosterone and in trials lasting 12 months or more.

The 2016 Testosterone and Atherosclerosis in Aging Men (TAAAM) trial (N=308) found similar lean mass gains but also noted that men who combined TRT with resistance training gained roughly 40% more lean mass than those on TRT alone [8]. That interaction is well-supported mechanistically: testosterone increases satellite cell activation, and mechanical load from resistance exercise amplifies that signal through IGF-1 upregulation.

Dose matters. The canonical dose-escalation data from Bhasin et al. in NEJM (2001) showed lean mass gains plateaued near physiologic replacement doses (roughly 100-125 mg/week of testosterone enanthate in that study's pharmacokinetic model) [1]. Supraphysiologic doses added marginally more muscle but substantially increased erythrocytosis and cardiovascular risk markers.

TRT for Low Libido: Response Rates and Timeline

Low libido is the most consistently testosterone-responsive sexual symptom. A 2010 systematic review of 17 RCTs in the Annals of Internal Medicine found TRT improved sexual desire in 64% of hypogonadal men within 3-6 weeks [9]. Effect size was largest in men with the lowest baseline testosterone, particularly those below 200 ng/dL.

Libido recovery is not instantaneous. Most men report improved desire within 3-6 weeks of reaching stable testosterone levels. Research published in the Journal of Sexual Medicine (2011) found that sexual motivation scores peaked at approximately 3 months and remained stable through 12 months of follow-up [10]. Men who expected overnight results were more likely to discontinue treatment prematurely before full benefit appeared.

Testosterone is necessary but not always sufficient for libido. Depression, relationship stress, sleep apnea, medications such as SSRIs, and opioid use all suppress desire through testosterone-independent pathways. A thorough intake should screen for those contributors before attributing low libido to testosterone alone.

TRT for Erectile Dysfunction: What the Evidence Shows

The relationship between testosterone and erection is real but conditional. Testosterone maintains nitric oxide synthase expression in penile smooth muscle, which drives vasodilation and erection. Without adequate testosterone, even normal psychological arousal may fail to produce sufficient nitric oxide for full erection [11].

A 2016 placebo-controlled trial published in JCEM (N=140 hypogonadal men) found testosterone undecanoate significantly improved IIEF-EF domain scores by 5.8 points versus 1.2 points in placebo at 30 weeks (P<0.001) [11]. Approximately 57% of testosterone-treated men achieved a clinically meaningful response (IIEF-EF increase of at least 4 points).

However, the Princeton Consensus III guidelines, summarized in the Journal of Sexual Medicine note that ED in men with testosterone in the low-normal range (300-400 ng/dL) responds poorly to testosterone alone [12]. In that group, PDE5 inhibitors such as sildenafil 50-100 mg or tadalafil 5 mg daily are the evidence-based first line. Combination therapy, testosterone plus a PDE5 inhibitor, shows additive benefit in men with both low testosterone and vasculogenic ED.

The AUA 2018 Erectile Dysfunction Guidelines state: "Testosterone therapy is not recommended as a primary treatment for ED in men without hypogonadism" [12]. Hypogonadism must be biochemically confirmed, not assumed.

How TRT Is Dosed and Monitored

Several delivery systems are FDA-approved. Testosterone cypionate or enanthate given intramuscularly at 100-200 mg every 7-14 days remains the most cost-effective option [13]. Testosterone undecanoate (Aveed) 750 mg IM is dosed at weeks 0, 4, then every 10 weeks, offering convenience but higher cost. Topical gels such as AndroGel 1.62% (40.5-81 mg/day) avoid injection site issues but carry transfer risk to partners and children. Subcutaneous pellets (Testopel) deliver 75-150 mg per pellet every 3-6 months.

The FDA label for testosterone cypionate specifies dose titration to achieve serum testosterone in the mid-normal range of 400-700 ng/dL [13]. Checking a trough level (for injections: drawn immediately before the next dose) at 6-8 weeks guides adjustment.

Monitoring follows a standard schedule per Endocrine Society guidelines:

• 3 months: Serum total and free testosterone (trough for injections), hematocrit, PSA, blood pressure.
• 12 months: Repeat all above plus lipid panel, bone mineral density if osteoporosis risk is present.
• Ongoing annually thereafter as long as therapy continues [3].

Hematocrit above 54% requires dose reduction or phlebotomy because of thrombosis risk. PSA rises above 1.4 ng/mL from baseline within 12 months prompt urology referral [3].

Who Qualifies for TRT: Diagnostic Criteria

Qualification for TRT requires both biochemical and symptomatic criteria. The American Urological Association (AUA) 2018 guideline defines testosterone deficiency as total testosterone below 300 ng/dL confirmed on two separate morning (7-10 AM) samples paired with symptoms [14]. Symptoms that count include decreased libido, fatigue, reduced muscle mass, increased body fat, depressed mood, poor concentration, and reduced bone density.

Common causes of secondary hypogonadism include obesity (BMI above 35 lowers testosterone by an average of 100 ng/dL per a 2015 meta-analysis in Obesity Reviews), opioid use, hyperprolactinemia, and pituitary adenomas [15]. These causes should be excluded or treated before TRT begins, because correcting the root cause (for example, weight loss achieving 10% body weight reduction) may normalize testosterone without exogenous therapy.

Men under 35 with secondary hypogonadism who want children are generally better served by hCG or clomiphene first [4]. TRT is contraindicated in men with a history of estrogen-sensitive prostate cancer, untreated severe obstructive sleep apnea, hematocrit above 50% at baseline, or plans for near-term fertility [3].

Safety Profile: Real Risks and How They Are Managed

TRT is not free of risk, and the largest concern in the past decade has been cardiovascular. The 2010 Testosterone in Older Men with Mobility Limitations (TOM) trial (N=209) was stopped early after a higher rate of cardiovascular adverse events in the testosterone arm (23 events vs. 5 in placebo) [16]. Critically, that study used supraphysiologic doses in frail elderly men with pre-existing cardiovascular disease, limiting its generalizability.

The larger TRAVERSE trial (N=5,246), published in NEJM in 2023, was designed specifically to answer the cardiovascular safety question in men aged 45-80 with low testosterone and elevated cardiovascular risk [17]. TRAVERSE found no significant difference in major adverse cardiovascular events (MACE) between testosterone gel and placebo over a mean of 33 months (hazard ratio 0.96 to 95% CI 0.83-1.12). Atrial fibrillation was more common in the testosterone group (3.5% vs. 2.4%, P=0.02), as was pulmonary embolism (0.9% vs. 0.5%, P=0.03) [17]. Those findings argue for caution in men with pre-existing atrial fibrillation or prior VTE.

Erythrocytosis (hematocrit above 54%) occurs in approximately 5% of men on injectable testosterone and is the most common dose-dependent side effect requiring intervention [3]. Dose reduction to 75 mg every 10-14 days or a switch to topical administration usually resolves it. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis within 6-8 weeks, causing testicular atrophy and azoospermia. Adding hCG 500 IU three times weekly can preserve testicular volume and sperm production in men on TRT who have fertility concerns [4].

Andropause and Late-Onset Hypogonadism: A Clinical Frame

Andropause is not a discrete event like menopause. Testosterone falls gradually, and the threshold at which symptoms appear varies widely between individuals. The EMAS study in NEJM (2010) identified three sexual symptoms as the most testosterone-specific indicators: low libido, poor spontaneous erections, and erectile dysfunction [5]. Non-sexual symptoms such as fatigue, depressed mood, and poor concentration were common in the aging population regardless of testosterone level and therefore less diagnostically specific.

Men who present with andropause symptoms should have testosterone measured, but they should also be screened for sleep apnea, thyroid disease, depression, and anemia before attributing symptoms to testosterone deficiency. A normal testosterone level in a symptomatic man does not exclude late-onset hypogonadism if free testosterone is low (below 65 pg/mL by equilibrium dialysis) due to elevated sex hormone-binding globulin (SHBG) [3].

Treatment of late-onset hypogonadism follows the same dosing and monitoring protocols above but with particular attention to bone mineral density. A 12-month RCT published in NEJM in 2016, part of the TTrials, showed testosterone treatment increased bone mineral density in the lumbar spine by 7.5% and in the femoral neck by 4.1% versus placebo in men with low testosterone and osteopenia [18].

Optimizing Results: Resistance Training, Nutrition, and Adjunct Considerations

TRT produces better lean mass results when combined with structured exercise. The 2004 RCT by Bhasin et al. in JCEM (N=61 older men) showed that testosterone plus resistance training produced 4.3 kg of lean mass gain over 20 weeks, compared to 2.2 kg with testosterone alone and 1.0 kg with resistance training alone [19]. That additive effect supports a combined approach rather than relying on either intervention separately.

Protein intake supports the anabolic response. A 2018 systematic review in the British Journal of Sports Medicine covering 49 RCTs (N=1,863) found protein supplementation of at least 1.6 g/kg/day maximized lean mass gains from resistance training in older men [20]. Men on TRT should aim for that intake, prioritizing leucine-rich sources such as whey protein, eggs, or lean meat.

Sleep quality also matters. A 2011 study in JAMA showed that one week of sleep restricted to 5 hours per night reduced testosterone by 15% in healthy young men [21]. Men who achieve TRT target testosterone levels but sleep fewer than 6 hours nightly may see blunted benefits from treatment.